COMMENT: The new craze of using lower-than-recommended dosages of weight loss drugs to slim down might sound tempting, says ...

Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its ...

before being randomized to receive a single administration of Vivani’s exenatide implant (NPM-115, n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide ...

Rybelsus (semaglutide) is the first GLP-1 agonist ... "providing patients with another option to treat the disease without injections," according to the panel. The new oral drug is viewed as ...

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...